CTXR

Citius Pharmaceuticals Inc

May 20 • 04:00PM ET

0.5800

+0.0258 4.66 %

Healthcare • Biotechnology • USA • Nano • NASD

May 18, 8:31 PMQ2 earnings miss and $19.7M CMO contract cancellation charge drive 25% drop.

Peers: IMNN BLRX TNXP BCDA BIVI

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.57	Insider Own	1.82%	Shs Outstand	27.45M	Perf Week	-10.77%
Market Cap	15.92M	Forward P/E	0.59	EPS next Y	0.99	Insider Trans	0.00%	Shs Float	26.95M	Perf Month	-31.35%
Enterprise Value	19.68M	PEG	-	EPS next Q	0.03	Inst Own	3.63%	Short Float	19.53%	Perf Quarter	-16.06%
Income	-46.20M	P/S	2.84	EPS this Y	96.89%	Inst Trans	4.48%	Short Ratio	6.72	Perf Half Y	-37.97%
Sales	5.61M	P/B	0.21	EPS next Y	1042.86%	ROA	-36.38%	Short Interest	5.26M	Perf YTD	-25.35%
Book/sh	2.75	P/C	3.47	EPS next 5Y	-	ROE	-75.61%	52W High	2.48 -76.61%	Perf Year	-21.47%
Cash/sh	0.17	P/FCF	-	EPS past 3/5Y	16.24% 21.29%	ROIC	-74.30%	52W Low	0.48 21.85%	Perf 3Y	-98.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	37.36%	Volatility	12.87% 10.31%	Perf 5Y	-98.97%
Dividend TTM	-	EV/Sales	3.51	EPS Y/Y TTM	55.15%	Oper. Margin	-1041.44%	ATR (14)	0.08	Perf 10Y	-99.88%
Dividend Ex-Date	-	Quick Ratio	0.16	Sales Y/Y TTM	-	Profit Margin	-823.34%	RSI (14)	40.30	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.58	EPS Q/Q	25.41%	SMA20	-13.28%	Beta	1.04	Target Price	5.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-23.69%	Rel Volume	1.15	Prev Close	0.55
Employees	23	LT Debt/Eq	0.01	Earnings	May 15 AMC	SMA200	-43.41%	Avg Volume	783.52K	Price	0.58
IPO	Oct 02, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-238.32% -83.70%	Trades		Volume	900,275	Change	4.66%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Upgrade	D. Boral Capital	Hold → Buy	$9
Nov-30-21	Initiated	Maxim Group	Buy	$4

May-15-26 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire) -24.76%
04:30PM	Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Apr-29-26 08:00AM	Citius Oncology Ships First International Order of LYMPHIR to Europe (PR Newswire) -8.46%
Apr-24-26 04:30PM	Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire) -17.47% -10.26%
10:48AM	Citius Pharmaceuticals Secures $5M Through Equity Offering (InvestorsHub)
08:00AM	Loading…
08:00AM	Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Mar-31-26 09:11AM	Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development (PR Newswire) +32.28%
Mar-24-26 08:00AM	Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts (PR Newswire) -5.48%
Mar-10-26 08:47AM	Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers (PR Newswire) +10.97%
Mar-06-26 03:00PM	Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR (Insider Monkey) -11.97%
Feb-24-26 08:00AM	Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program (PR Newswire) +12.65%
Feb-13-26 08:00AM	Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR (PR Newswire)
08:00AM	Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR (PR Newswire)
Feb-12-26 06:55AM	Citius Oncology and Uniphar sign European distribution deal for Lymphir (Pharmaceutical Technology) -11.78%
Feb-11-26 08:00AM	Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar (PR Newswire) +10.82%
04:30PM	Loading…
Dec-23-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire) -23.02%
04:30PM	Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire)
Dec-09-25 08:30AM	Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) +7.14%
Dec-04-25 08:37AM	Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim (PR Newswire) +9.17%
Dec-01-25 12:00PM	Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) (PR Newswire) -6.25%
Nov-21-25 08:37AM	Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration (PR Newswire) +15.15%
Oct-21-25 04:30PM	Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire) -7.18% -6.55%
08:00AM	Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Oct-20-25 08:37AM	Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR Commercial Launch (PR Newswire) +24.83%
Oct-17-25 05:00PM	Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences (PR Newswire)
Oct-16-25 08:47AM	Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR (PR Newswire) +6.47%
Sep-10-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Sep-09-25 08:30AM	Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Aug-22-25 08:47AM	Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch (PR Newswire) +9.76%
Aug-12-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
04:30PM	Loading…
04:30PM	Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Jul-17-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Public Offering (PR Newswire) +7.05%
Jul-16-25 09:15AM	Citius Oncology Announces Pricing of $9.0 Million Public Offering (PR Newswire) -8.59%
Jul-15-25 08:32AM	Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora (PR Newswire)
Jul-08-25 08:34AM	Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) -8.08%
Jul-06-25 04:01AM	Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR (Insider Monkey)
Jun-17-25 08:08AM	Citius Oncology Anticipates Commercial Launch of LYMPHIR in 2025 (PR Newswire) +8.00%
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire) -8.91%
08:35AM	Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Jun-10-25 07:00AM	Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire) -22.63%
Jun-09-25 08:37AM	Citius Oncology Enters into Distribution Services Agreement with Cardinal Health (PR Newswire) +60.99%
May-14-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire) +19.20% -11.74%
May-05-25 08:37AM	Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (PR Newswire) +5.33%
Apr-01-25 09:00AM	Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock (PR Newswire) -19.46%
Feb-14-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -8.18%
Feb-06-25 08:55AM	Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services (PR Newswire)
Jan-08-25 08:00AM	Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (PR Newswire) -15.10%
Jan-07-25 08:08AM	Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 (PR Newswire) +11.76%
07:57AM	Citius Oncology to explore strategic alternatives (TipRanks)
Jan-06-25 07:50AM	Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives (PR Newswire)
Dec-31-24 07:10AM	Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital (TipRanks)
Dec-30-24 09:43AM	American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls (The Fly) +6.25%
Dec-29-24 10:50PM	Citius Pharma Reports 2024 Financial Results and Business Update (TipRanks)
Dec-27-24 05:00PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire) +11.18% +6.25%
Nov-25-24 08:03AM	Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok Program and Pathway to Approval (PR Newswire)
Nov-22-24 09:00AM	Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split (PR Newswire) -18.96%
Nov-18-24 04:05PM	Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering (PR Newswire) +12.10% -14.45%
Nov-15-24 01:30PM	Citius Pharmaceuticals Announces $3 Million Registered Direct Offering (PR Newswire) -39.10%
Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +9.16%
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)
Aug-13-24 09:30AM	Sidoti Events, LLC's Virtual August Micro-Cap Conference (ACCESSWIRE) -11.69%
04:32AM	Citius merges oncology subsidiary with TenX Keane (Pharmaceutical Technology)
Aug-12-24 10:53PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024 (InvestorPlace) -11.38%
05:28PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
04:22PM	Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. (PR Newswire)
08:00AM	Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments (PR Newswire)
Aug-09-24 07:30AM	TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update (GlobeNewswire) -12.36%
Aug-08-24 05:41PM	Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection (Benzinga)
06:59AM	Citius Pharmaceuticals Receives FDA Approval for LYMPHIR (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Aug-05-24 08:00AM	TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals (GlobeNewswire)
08:00AM	Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. (PR Newswire)
Jul-18-24 07:00AM	Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL) (Newsfile)
Jul-17-24 08:00AM	Analysts Hunt for Undervalued Biotech Stocks (Newsfile)
Jul-11-24 11:00AM	Bloodstream Infections - From Threats to Solutions (Newsfile)
08:00AM	Biopharma Stocks Transformative Innovation for the Future of Health (Newsfile)
Jul-10-24 09:10AM	Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates (PR Newswire) +10.29%
Jul-07-24 09:01AM	2 Biotech Stocks With Big FDA Decisions Approaching Heres What Analysts Expect (TipRanks)
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
May-29-24 08:30AM	Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
May-21-24 11:42AM	Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue (InvestorPlace) +10.64%
11:20AM	VFS Stock Alert: VinFast Plunges on NHTSA Probe (InvestorPlace)
10:58AM	Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today? (InvestorPlace)
07:00AM	Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
May-14-24 10:55PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024 (InvestorPlace) -9.15%
04:05PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-10-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences (PR Newswire)
Apr-30-24 04:05PM	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering (PR Newswire) +7.85%
Apr-26-24 10:43AM	Citius Pharmaceuticals Launches $15 Million Offering (MT Newswires) -9.25%
08:00AM	Citius Pharmaceuticals Announces $15 Million Registered Direct Offering (PR Newswire)
Apr-11-24 08:30AM	Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma (PR Newswire)
Apr-04-24 08:30AM	Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference (PR Newswire)
Mar-18-24 08:30AM	Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
Mar-07-24 08:30AM	Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program (PR Newswire)
Feb-26-24 07:30AM	Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration (PR Newswire)
Feb-23-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences (PR Newswire)
Feb-15-24 09:17AM	Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials (GuruFocus.com) +9.12%
Feb-14-24 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update (PR Newswire) +13.51%
08:01AM	Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.

Co-FounderMr. Leonard L. Mazur

Co-Founder & Executive Vice ChairmanMr. Myron Z. Holubiak

Executive VP & Chief Medical OfficerDr. Myron S. Czuczman M.D.

Chief Business Officer & CFOMr. Jaime Bartushak

Executive Vice President of OperationsMr. Gary F. Talarico

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTXR

Citius Pharmaceuticals Inc

Upgrade your Finviz experience